Today, Peter Menziuso and Carol Lakkis, BScOptom, Ph.D., represented Johnson & Johnson Vision alongside other key stakeholders in Washington, D.C., at the Federal Trade Commission’s (FTC) public workshop.
The public workshop was held as part of the FTC’s scheduled, 10-year review of the Contact Lens Rule and provided an opportunity for eye health advocates to share their perspective on the FTC’s 2017 proposed changes.
During their panels, Mr. Menziuso and Dr. Lakkis raised how changes to the Contact Lens Rule may impact the current regulatory framework that preserves the patient-doctor relationship, and ensures patients’ access to innovative contact lens technologies while minimizing health related risks – both now and in the future.
Mr. Menziuso and Dr. Lakkis were also joined by a range of leaders in optometry, including several staff optometrists and medical experts from Johnson & Johnson Vision who came to D.C. to show their support for the profession and the patients they serve.
As part of Johnson & Johnson Vision’s broader, ongoing effort to engage lawmakers, Mr. Menziuso and other members of the leadership team also met with Senator Bill Nelson [D-FL] this week to discuss the importance of policies that promote optimal eye health alongside consumer choice and competition.
Mr. Menziuso is President, North America, Johnson & Johnson Vision Care, Inc., and Dr. Lakkis is Clinical Research Fellow and Head of Applied Clinical Science for Johnson & Johnson Vision Care, Inc.
“We know that the roles of eye health, eye doctors, and contact lens safety are essential to fostering manufacturer innovation, patient choice, and competition in the marketplace. That’s why we remain committed to working alongside the FTC and patient advocates to ensure our regulatory framework continues to maximize patient eye health benefits and bolster consumers’ access to contact lenses in states across the country.”
— Peter Menziuso, President, North America
Johnson & Johnson Vision Care, Inc.